Frontlight ResearchEarly access
Liver and biliary tract cancer trials in China
619 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peoplePhase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Where
- Beijing, Bengbu, Changchun, Dalian, Dongguan, Fuzhou, Guangzhou, Haerbin, Hangzhou, Jinan, Kunming, Nanchang, Shanghai, Shenyang, Taiyuan, Tianjin, Ürümqi, Xiamen, Zhengzhou, Zhuhai
- Age
- 18 years and over
- People
- 170
- Run by
- 3D Medicines (Sichuan) Co., Ltd.
See details and how to joinNCT05024214 - Phase 1/2Taking peopleAdebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
- Where
- Wuhan
- Age
- 18 years and over
- People
- 29
- Run by
- Tongji Hospital
See details and how to joinNCT07392541 - No phaseTaking peoplecfDNA Methylation for Liver Cancer Recurrence Detection
- Where
- Wuhan
- Age
- 18 years and over
- People
- 500
- Run by
- Wuhan Ammunition Life-tech Co., Ltd
See details and how to joinNCT07466602 - No phaseTaking peoplePrediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
- Where
- Foshan, Guangzhou, Shaoguan
- Age
- 18 years to 75 years
- People
- 255
- Run by
- Zhujiang Hospital
See details and how to joinNCT06157060 - Phase 1/2Taking peopleA Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
- Where
- Chengdu
- Age
- 18 years to 80 years
- People
- 33
- Run by
- West China Hospital
See details and how to joinNCT07482059 - No phaseNot yet taking people in ChinaSafety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
- Where
- Chengdu
- Age
- 18 years to 80 years
- People
- 30
- Run by
- Hong Wu
See details and how to joinNCT07480382 - Phase 2Taking peopleA Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 100
- Run by
- Akeso
See details and how to joinNCT07052253 - Phase 1Taking peoplePhase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- Where
- Beijing, Bengbu, Changchun, Changsha, Chengdu, Dongguan, Fuzhou, Ganzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Lishui, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi’an, Zhengzhou
- Age
- 18 years to 65 years
- People
- 246 worldwide
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT07176650 - Phase 2Not yet taking people in ChinaA Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)
- Where
- Nanjing
- Age
- 18 years to 70 years
- People
- 25
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07471165 - Phase 2Taking peopleHepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)
- Where
- Chengdu
- Age
- 18 years to 75 years
- People
- 25
- Run by
- West China Hospital
See details and how to joinNCT06859684 - Phase 1Taking peopleStudy of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Where
- Beijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- Age
- 18 years and over
- People
- 330 worldwide
- Run by
- I-Mab Biopharma US Limited
See details and how to joinNCT04900818 - Phase 1/2Taking peopleA Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
- Where
- Beijing, Jinan
- Age
- 18 years to 75 years
- People
- 280
- Run by
- Akeso
See details and how to joinNCT06530251 - Phase 1/2Taking peopleA Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 135
- Run by
- Akeso
See details and how to joinNCT06938321 - No phaseTaking peopleSafety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
- Where
- Beijing, Chengdu, Xuzhou
- Age
- 18 years to 80 years
- People
- 200
- Run by
- West China Hospital
See details and how to joinNCT07295275 - No phaseTaking peopleImpact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 90
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT07436845 - Phase 2Enrolling by invitationA Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
- Where
- Hubei
- Age
- 18 years and over
- People
- 118
- Run by
- Abbisko Therapeutics Co, Ltd
See details and how to joinNCT05441475 - Phase 1/2Taking peopleBiomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
- Where
- Beijing
- Age
- 8 years to 85 years
- People
- 85
- Run by
- Essen Biotech
See details and how to joinNCT07410494 - Phase 1/2Taking peopleEBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
- Where
- Beijing
- People
- 83
- Run by
- Essen Biotech
See details and how to joinNCT07410676 - Phase 3Taking peopleAdjuvant TACE in HCC With High-risk Recurrence Factors
- Where
- Nanning
- Age
- 18 years to 70 years
- People
- 442
- Run by
- Guangxi Medical University
See details and how to joinNCT07417397 - No phaseTaking peopleA Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain
- Where
- Wuhan
- People
- 103
- Run by
- Tongji Hospital
See details and how to joinNCT07326137 - Phase 2Taking peoplePD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 62
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT05430698 - Phase 2/3Not yet taking people in ChinaA Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
- Where
- Nanjing, Shanghai
- Age
- 18 years to 75 years
- People
- 120
- Run by
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
See details and how to joinNCT07392866 - Phase 2Taking peopleCosiporfin Sodium for Injection Photodynamic Therapy
- Where
- Shanghai
- Age
- 18 years and over
- People
- 30
- Run by
- Shanghai Guangsheng Biopharmaceutical Co., Ltd
See details and how to joinNCT07398339 - Phase 1Taking peopleMDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
- Where
- Fuzhou, Guangzhou, Hangzhou, Hefei, Henan, Jinan, Nanjing, Shanghai
- Age
- 18 years to 80 years
- People
- 40
- Run by
- Suzhou Mednovo Yi Medical Technology Co., Ltd.
See details and how to joinNCT07391839 - Phase 1Taking peopleA Study of SH009 Injection in Patients With Advanced Solid Tumors.
- Where
- Shanghai
- Age
- 18 years and over
- People
- 150
- Run by
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
See details and how to joinNCT07390838